Loading provider…
Loading provider…
Anatomic Pathology & Clinical Pathology Physician in Fullerton, CA
NPI: 1396037537Primary Practice Location
PROVIDENCE ST. JUDE MEDICAL CENTER
101 E Valencia Mesa Dr, Fullerton, CA
Primary Employer
THE PATHOLOGY GROUP INC
HQ Phone
Get M.D. Mark's Phone Numberphone_androidMobile
Get M.D. Mark's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2013 - 2027

American Board of Pathology
Pathology - Anatomic/Pathology - Clinical

American Board of Pathology
Cytopathology
University of Southern California/Los Angeles General Medical Center (USC/LA General)
Fellowship • Cytopathology
2016 - 2017
Residency • Pathology-Anatomic and Clinical
2011 - 2015
University of Southern California/Los Angeles General Medical Center (USC/LA General) Surgical Pathology
Fellowship • Selective Pathology
2015 - 2016
New York Medical College
nymc.edu
Medical School
Until 2011
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 88305Pathology examination of tissue using a microscope, intermediate complexity | 621 | 1,012 |
| 2 | 88304Pathology examination of tissue using a microscope, moderately low complexity | 160 | 165 |
| 3 | 88311Preparation of tissue for examination by removing any calcium present | 127 | 132 |
| 4 | 88342Tissue or cell analysis by immunologic technique | 101 | 127 |
| 5 | 88307Pathology examination of tissue using a microscope, moderately high complexity | 88 | 163 |
Authors: Vasquez, Ivan, Tan, Nhi, Boonyasampant, Mark, Koppitch, Kari A, Lansman, Jeffry B
Journal: J Physiol
Publication Date: 2012-09-10
Life‐threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab